Roughly half of people with diabetes develop peripheral neuropathy over the course of their disease, and in 30–40% of those cases the nerve damage is painful rather than silent. Painful diabetic neuropathy (PDN) produces burning, shooting, or electric-shock sensations in the feet and lower legs, often worse at night, and it is consistently associated with sleep disruption, mood disorders, and reduced quality of life. It is also one of the more difficult symptoms in diabetes care to treat well: fewer than one-third of patients achieve satisfactory pain relief with currently available drugs. Understanding what the evidence actually shows — and what it does not — helps set realistic expectations for treatment.
Diagnosis Comes First, and It Is Not Always Straightforward
In a 2021 review in Brain, Jensen and colleagues emphasized that there is no single diagnostic gold standard for distal symmetric polyneuropathy or its painful variant. Diagnosis in research settings relies on a hierarchical combination of symptoms, clinical signs, and confirmatory testing such as nerve conduction studies, quantitative sensory testing, or intraepidermal nerve fibre density. In everyday practice, the diagnosis rests largely on history and bedside sensory examination.
Two points matter clinically. First, painful neuropathy and loss of protective sensation can coexist — a foot that hurts may still be insensate to injury. Second, pain is not a reliable marker of neuropathy severity; patients with minimal measurable nerve deficit can have severe pain, and patients with profound sensory loss may have none. The same review noted that more detailed sensory phenotyping may eventually allow treatments to be matched to underlying mechanisms rather than prescribed by trial and error.
First-Line Drug Therapy: Comparable Effect Sizes Across Classes
The American Academy of Neurology updated its practice guideline on oral and topical treatment of painful diabetic polyneuropathy in 2022 (Price et al., Neurology). Pooling trials published between 2008 and 2020, the subcommittee reported broadly similar standardized mean differences for gabapentinoids (0.44), serotonin–norepinephrine reuptake inhibitors (0.47), sodium channel blockers (0.56), and SNRI/opioid dual-mechanism agents (0.62). Tricyclic antidepressants showed a larger effect size (0.95) but with low confidence in that estimate.
The guideline recommends that clinicians assess patients with diabetes for painful neuropathy and screen those affected for concurrent mood and sleep disorders; offer a tricyclic antidepressant, SNRI, gabapentinoid, or sodium channel blocker; consider factors beyond efficacy such as comorbidities, cost, and side-effect profile; switch to a different drug class when a trial fails; and not use opioids for this indication.
A 2025 systematic review and meta-analysis by Soliman and colleagues in The Lancet Neurology, covering 313 trials and 48,789 participants with neuropathic pain of various causes, reached similar conclusions. Numbers needed to treat were 4.6 for tricyclic antidepressants, 7.4 for SNRIs, and 8.9 for α2δ-ligands (gabapentin and pregabalin), supporting a strong recommendation for all three as first-line therapy. Capsaicin 8% patches and 5% lidocaine plasters were given weak second-line recommendations, and botulinum toxin, repetitive transcranial magnetic stimulation, and opioids weak third-line recommendations.
Combination Therapy When Monotherapy Falls Short
The OPTION-DM trial (Tesfaye et al., The Lancet, 2022) remains the largest head-to-head comparison in this field — a 13-centre, double-blind crossover study of 140 patients comparing amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin. Mean daily pain scores fell from 6.6 to 3.3 out of 10 across all three pathways, with no significant difference between them. The clinically useful finding was that patients whose pain remained above 3/10 on monotherapy and were then given a second agent achieved a further mean reduction of 1.0 points, compared with 0.2 in those who stayed on monotherapy. Adverse effects were class-predictable: dizziness with pregabalin, nausea with duloxetine, and dry mouth with amitriptyline.
Beyond Oral Drugs: Neuromodulation and Disease-Directed Therapy
For pain refractory to medication, D’Souza and colleagues (Current Pain and Headache Reports, 2022) reviewed level I evidence supporting dorsal column spinal cord stimulation using either 10-kHz or conventional tonic waveforms. This is an invasive option reserved for carefully selected patients after adequate pharmacological trials have failed.
A separate line of work addresses the neuropathy itself rather than the pain. Ziegler (Diabetes Research and Clinical Practice, 2023) described three pillars of management: causal treatment through lifestyle modification, near-normoglycaemia, and multifactorial cardiovascular risk reduction; pathogenesis-oriented pharmacotherapy such as α-lipoic acid, benfotiamine, and epalrestat, authorized in some countries; and symptomatic analgesia. Notably, intensive glycemic control shows clearer benefit for neuropathy prevention in type 1 than in type 2 diabetes.
Key Takeaways
Current first-line agents for painful diabetic neuropathy — tricyclic antidepressants, SNRIs, and gabapentinoids — have modest and largely comparable efficacy, so drug selection is often driven by comorbidities, tolerability, and cost rather than expected pain relief. When one class fails, switching classes is appropriate; when monotherapy gives partial relief, adding a second agent produces further benefit and is generally well tolerated. Opioids are not recommended. Because painful neuropathy frequently coexists with sleep and mood disturbance, and because pain does not exclude loss of protective sensation, assessment should extend beyond the pain score to the foot itself.
References
- Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022;98(1):31–43.
- Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. The Lancet. 2022;400(10353):680–690.
- Soliman N, Moisset X, Ferraro MC, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. The Lancet Neurology. 2025;24(5):413–428.
- Jensen TS, Karlsson P, Gylfadottir SS, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144(6):1632–1645.
- D’Souza RS, Barman R, Joseph A, Abd-Elsayed A. Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review. Current Pain and Headache Reports. 2022;26(8):583–594.
- Ziegler D. Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Research and Clinical Practice. 2023;206(Suppl 1):110764.
Comments
